person

Olga B.

Country
The Netherlands
Department
#2914:Cardiology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
363
Sites with multiple studies

Has run more than one trial at 363 of 416 partner sites.

Specializations

Cardiovascular Prevention

The investigator specializes in primary prevention of atherosclerotic cardiovascular disease (ASCVD), focusing on innovative therapeutic approaches for high-risk patients. Their research encompasses the evaluation of novel treatments for reducing cardiovascular risks.

  • Cardiovascular Risk Management
  • Preventive Cardiology
  • Atherosclerosis Prevention

Their work extends to investigating interventions that may prevent major adverse cardiovascular events in patients requiring primary prevention strategies.

Clinical Outcomes Research

The investigator studies comprehensive cardiovascular endpoints including cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke. Their research evaluates therapeutic interventions aimed at improving patient outcomes.

  • Cardiovascular Endpoints
  • Emergency Coronary Care
  • Stroke Prevention

Their expertise includes assessment of urgent coronary interventions and their impact on patient health outcomes.

Therapeutic Innovation

The investigator focuses on evaluating new therapeutic agents for cardiovascular risk reduction. Their research involves assessment of novel compounds for managing cardiovascular health in high-risk populations.

  • Novel Therapeutic Approaches
  • Risk Factor Modification
  • Preventive Medicine

Their work contributes to advancing therapeutic options in preventive cardiology and cardiovascular medicine.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.